Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic

Mazdutide

$87.00 – $115.00 Select options

Mazdutide

Price range: $87.00 through $115.00

Research-grade Mazdutide (IBI362/LY3305677) is a synthetic 39-amino-acid dual agonist peptide targeting GLP-1R and GCGR receptors that is designed for controlled investigations of appetite suppression, energy expenditure, glycemic control, and synergistic incretin therapy in obesity and diabetes models.

Size: No selection

More options

Clear

Mazdutide is an investigational unimolecular dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), developed by Eli Lilly and Innovent Biologics as an analog of oxyntomodulin. It combines GLP-1’s insulinotropic and satiety effects with glucagon’s energy-expending properties for enhanced metabolic regulation. Currently in Phase 3 trials (GLORY program) for obesity and type 2 diabetes, Phase 2 data show up to −15.6% body weight loss at 52 weeks (4.5 mg dose). This research-grade lyophilized powder is synthesized under strict quality controls and provided with full analytical documentation, ideal for metabolic, incretin, and cardiometabolic research.

Key Scientific

High-purity Mazdutide (≥ 98% by HPLC/MS, acetate salt form)
Verified 39-amino-acid sequence based on oxyntomodulin scaffold with modifications for dual agonism
Lyophilized formulation for maximum long-term stability
Full Certificate of Analysis (COA) with HPLC, MS, and receptor-binding assays (GLP-1R/GCGR EC50)
Manufactured in GMP-aligned, ISO-compliant facilities
Ideal for dual-agonist signaling, weight management, and T2D pathway studies

Research-Referenced Attributes (Based on published clinical/preclinical literature; not therapeutic claims.)

Dual GLP-1R/GCGR activation → superior weight loss (−10.8% to −15.6% at 52 weeks) vs. placebo or liraglutide
Significant HbA1c reduction (−1.46% to −2.23%) and fasting glucose improvement in T2D trials
Enhanced satiety, gastric emptying delay, and energy expenditure with once-weekly dosing
Improves cardiometabolic markers: triglycerides (−42–60%), BP, and insulin sensitivity
Potential in NAFLD/MASH and cognitive dysfunction via glutamate excitotoxicity modulation
Favorable tolerability with mild GI effects; no major CV risks in Phase 2/3 data

Why Researchers Choose Nationwide Peptides Mazdutide

Exact clinical-sequence match to IBI362/LY3305677 with verified dual-receptor affinity
Highest potency for GLP-1R/GCGR studies among research suppliers
Transparent analytical data (HPLC >98%, MS confirmation)
Trusted by metabolic endocrinology, obesity, and pharmacology laboratories
Competitive research pricing with bulk options

Storage & Handling

Store lyophilized powder at –4 °F (long-term) or 39.2 °F (short-term)
Store in a tightly sealed container and protect from light, moisture, air exposure, and elevated temperatures.
Reconstitute only with bacteriostatic water or sterile saline (typical concentration 5–10 mg/mL)
Reconstituted solutions stable at 39.2 °F for up to 4 weeks; avoid repeated freeze-thaw cycles